Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01290575 · ClinicalTrials.gov registry record · Phase 1
Multiple Ascending Dose Study of BMS-820132 in Patients With Type 2 Diabetes
A Phase 1 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 1
- Development phase
- 67
- Enrollment target
NCT01290575 is a Phase 1 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 67 participants.
The verdict
NCT01290575, a Phase 1 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 67 participants
- Enrollment target
Study Summary
BMS-820132 is an investigational new drug being developed by BMS for treating Type 2 diabetes. The purpose of this study is to test the safety/tolerability (potential side effects) of multiple doses of the investigational new drug, as well as the amount of study drug in the blood and its effects on blood sugar,in subjects with type 2 diabetes.
Interventions
- DRUG Placebo
- DRUG BMS-820132
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 67 participants |
| Start Date | 2011-02 |
| Est. Completion | 2011-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01290575
The ClinicalTrials.gov registry entry for NCT01290575 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 67 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01290575 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01290575 about?
NCT01290575 is a clinical study titled "Multiple Ascending Dose Study of BMS-820132 in Patients With Type 2 Diabetes". BMS-820132 is an investigational new drug being developed by BMS for treating Type 2 diabetes. The purpose of this study is to test the safety/tolerability (potential side effects) of multiple doses of the investigational new drug, as well as the amount of study drug in the blood and its effects on ...
What is the current status of trial NCT01290575?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 67 participants. The study started on 2011-02. Estimated completion is 2011-11.
What interventions are being tested in trial NCT01290575?
The interventions under investigation include: Placebo (DRUG), BMS-820132 (DRUG).
Who is sponsoring clinical trial NCT01290575?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.